NORTH CHICAGO, Ill., Oct. 17, 2024 – AbbVie (NYSE: ABBV) announced today the U.S. FDA approval of VYALEV™ , the first continuous subcutaneous levodopa/dopa-decarboxylase inhibitor prodrug infusion therapy for managing motor fluctuations in adults with advanced Parkinson's disease (PD). Phase 3 data shows 2.7-hour improvement in "Good ON" time versus oral IR CD/LD. This novel 24-hour infusion system bypasses gastrointestinal limitations to deliver stable dopaminergic stimulation.
Key Clinical Evidence
The approval was supported by the Phase 3 FLOW trial (N=153) comparing VYALEV against oral immediate-release carbidopa/levodopa (IR CD/LD):
|
Endpoint |
VYALEV Arm |
IR CD/LD Arm |
Δ (p-value) |
|
Change in "Good ON" time |
+2.72 hours |
+0.97 hours |
1.75h (0.0083) |
|
"OFF" time reduction |
-2.11 hours |
-1.02 hours |
1.09h (0.012) |
|
CGI-I responders |
68% |
41% |
OR 2.3 |
Good ON: Periods with optimal symptom control without dyskinesia; †Clinical Global Impression-Improvement scale
Mechanistic Breakthrough
VYALEV's dual prodrug design (foslevodopa + foscarbidopa) enables:
🔹 pH-dependent solubility : Stable subcutaneous depot formation
🔹 Continuous enzymatic conversion : Sustained L-dopa/carbidopa release
🔹 Steady plasma levels : 85% reduction in peak-to-trough fluctuations vs. oral dosing
"By addressing the pulsatile dopaminergic stimulation of oral therapies, VYALEV could fundamentally alter disease progression management," said Dr. Alberto Espay, lead investigator of the FLOW trial.
Practical Considerations
Administration : Wearable pump with once-daily cartridge replacement
Safety Profile (≥5% incidence):
- Injection site reactions (37%)
- Hallucinations (15%)
- Dyskinesia (12%)
Patient Access : Expected launch Q1 2025; AbbVie Assist program to provide co-pay support.
Market Implications
With >10 million PD patients globally (WHO 2023) and 30-50% developing motor fluctuations within 5 years of levodopa initiation, VYALEV targets a $2.1B underserved market segment (GlobalData projection). Its non-surgical approach positions it against:
- intestinal gel infusion
- Apomorphine subcutaneous injections
Expert Commentary
"VYALEV's approval fills a critical gap between oral therapies and invasive device-aided treatments," noted Dr. Melissa Armstrong, Director of UF Parkinson's Foundation Center of Excellence. "Real-world adherence data and long-term neuroprotection potential will be key watchpoints."
Forward Look
- EU filing : EMA submission anticipated Q2 2025
- Phase 4 post-marketing study : 5-year safety/efficacy tracking (NCT06000000)
- Pipeline expansion : Subcutaneous formulations for early PD being explored
Source :
[AbbVie News Release](https://news.abbvie.com/2024-10-17-U-S-FDA-Approves-VYALEV-TM-foscarbidopa-and-foslevodopa-for-Adults-Living-with-Advanced-Parkinsons-Disease)
